BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Enrollment
- 80
- Primary Endpoint
- Association between BRAF, KRAS, and EGFR mutation status and clinical benefits (stable disease or partial response)
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in blood samples from patients with refractory non-small cell lung cancer previously treated with sorafenib tosylate.
Detailed Description
OBJECTIVES: * To determine the mutation rates of BRAF, KRAS, and EGFR in patients with non-small cell lung cancer treated with sorafenib tosylate on protocol ECOG-2501. * To determine the association between BRAF, KRAS, or EGFR mutation status and clinical benefits in patients treated with this regimen. OUTLINE: This is a multicenter study. DNA is isolated from archived plasma samples and analyzed for BRAF, KRAS, and EGFR mutations.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Association between BRAF, KRAS, and EGFR mutation status and clinical benefits (stable disease or partial response)
Time Frame: 1 month
Mutation rate of sorafenib tosylate-target gene BRAF, and its upstream proteins KRAS and EGFR
Time Frame: 1 mont